

**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript Type:** CASE REPORT

**Title:** Metastatic gastric cancer from breast carcinoma presenting with a rheumatic paraneoplastic syndrome

**Authors:** *Marília Bortoluz Rech. Eduarda Renz da Cruz. Karina Salgado, PhD., MD. Raul Angelo Balbinot, PhD, MD. Silvana Sartori Balbinot, PhD, MD. Jonathan Soldera, Prof, MSc, MD.*

**Corresponding Author:** Jonathan Soldera, Professor of Clinical Gastroenterology, School of Medicine, Universidade de Caxias do Sul, Ver Mário Pezzi Av, 699/801, Caxias do Sul - RS, CEP 95084-180, Brazil, Tel: 54-3039-3165; Email: [jonathansoldera@gmail.com](mailto:jonathansoldera@gmail.com)

## **ANSWER TO REVIEWERS**

### **REVIEWER 1:**

This manuscript reported a signet-ring cell adenocarcinoma with a metastasis of a breast carcinoma. The case is extremely rare and has great clinically significant.

*We would like to thank for the opportunity to improve our manuscript. Thank you for your valuable input.*

### **REVIEWER 2:**

In this manuscript, the authors made a case report of metastatic gastric cancer from breast carcinoma presenting with a rheumatic paraneoplastic syndrome.

The case was rare and could help us understand the biological, pathological and therapeutic choice for gastric metastasis from breast cancer. Several suggestions are as follows.

*Thank you for your suggestions and the opportunity to improve our manuscript.*

1. Please add the information of the molecular subtypes of breast cancer and metastatic gastric cancer, including ER, PR, HER2, Ki67.

*We have added a sentence describing the full immunohistochemistry report.*

2. If the IHC for ER is positive, why not choose endocrine therapy plus CDK4/6 inhibitor? Because the endocrine therapy is the standard therapy for metastatic ER+ breast cancer.

*She began treatment with endocrine therapy, but it failed to control the disease. We have described this in the paper now.*

3. Any other sites of metastasis? Visceral or bone metastasis?

*Yes, she had bone metastasis, as we have described in the paper.*

### **REVIEWER 3:**

*Thank you for your suggestions and the opportunity to improve our manuscript.*

1. The author should show the methods of treatment, including the chemotherapy regimen, usage and dosage of prednisone;

*We have described the dose of prednisone and the regimen of chemotherapy.*

2. The efficacy also needs to be described and provide evidence;

*We have added data on her laboratory results.*

3. It is better to mark the gastroscopy pictures for more intuitive.

*Thank you for your suggestion. We have added an arrow marking the erosion.*